Basic treatment considerations: Chemotherapy

Hematology/Oncology Clinics of North America

Volumn 18, Issue 1, 2004, Pages 13-28

  Ramalingam, Sakkaraiappan ^a   Belani, Chandra P ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; CANERTINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CISPLATIN DERIVATIVE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; IRINOTECAN; ISIS 3521; MONOCLONAL ANTIBODY; NAVELBINE; NITROSOUREA DERIVATIVE; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RADIOSENSITIZING AGENT; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINDESINE;

ADVANCED CANCER; ALOPECIA; ASTHENIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SCREENING; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; FLUID RETENTION; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOSENSITIZATION; RASH; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIDE EFFECT; SOLID TUMOR; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 1042298792     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(03)00136-9     Document Type: Review

References (106)

1. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol. 2:2001;533-543.
2. Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., Thun M.J. Cancer statistics, 2003. CA Cancer J Clin. 53:2003;5-26.
3. Henschke C.I., Yankelevitz D.F. Screening for lung cancer. J Thorac Imaging. 15:2000;21-27.
4. Pantel K., Izbicki J.R., Angstwurm M., Braun S., Passlick B., Karg O.et al. Immunocytological detection of bone marrow micrometastasis in operable non-small cell lung cancer. Cancer Res. 53:1993;1027-1031.
5. Passlick B., Kubuschok B., Izbicki J.R., Thetter O., Pantel K. Isolated tumor cells in bone marrow predict reduced survival in node-negative non-small cell lung cancer. Ann Thorac Surg. 68:1999;2053-2058.
6. Einhorn L.H., Fee W.H., Farber M.O., Livingston R.B., Gottlieb J.A. Improved chemotherapy for small-cell undifferentiated lung cancer. JAMA. 235:1976;1225-1229.
7. Cohen M.H. Small cell bronchogenic carcinoma. A prolonged remission following chemotherapy. JAMA. 237:1977;2528.
8. Einhorn L.H., Williams S.D., Stevens E.E., Bond W.H., Chenoweth L. Random prospective study cyclophosphamide, doxorubicin, and methotrexate (CAM) combination chemotherapy versus single-agent sequential chemotherapy in non small cell lung cancer. Cancer Treat Rep. 66:1982;2005-2011.
9. Livingston R.B. Nitrosourea combinations in lung cancer. Cancer Treat Rep. 60:1976;757-760.
10. Hansen H.H., Selawry O.S., Simon R., Carr D.T., van Wyk C.E., Tucker R.D.et al. Combination chemotherapy of advanced lung cancer: a randomized trial. Cancer. 38:1976;2201-2207.
11. Wittes R.E., Hopfan S., Hilaris B., Golbey R.B., Melamed M., Martini N. Oat cell carcinoma of the lung: combination treatment with radiotherapy and cyclophosphamide, adriamycin, vincristine, and methotrexate. Cancer. 40:1977;653-659.
12. Davis S., Pandya M.R., Rambotti P. Single-agent and combination chemotherapy for extensive non-small cell carcinomas of the lung. Cancer Treat Rep. 64:1980;685-688.
13. Hyde L., Wolf J., Phillips R., Mietlowski W. Combined chemotherapy for squamous cell carcinoma of the lung. Chest. 73:1978;603-607.
14. Bitran J.D., Desser R.K., DeMeester T., Golomb H.M. Metastatic non-oat-cell bronchogenic carcinoma. Therapy with cyclophosphamide, doxorubicin, methotrexate, and procarbazine (CAMP). JAMA. 240:1978;2743-2746.
15. Eagan R.T., Ingle J.N., Frytak S., Rubin J., Kvols L.K., Carr D.T.et al. Platinum-based polychemotherapy versus dianhydrogalactitol in advanced non-small cell lung cancer. Cancer Treat Rep. 61:1977;1339-1345.
16. Evans W.K., Feld R., DeBoer G., Osoba D., Curtis J.E., Baker M.A.et al. Cyclophosphamide, doxorubicin, and cisplatin in the treatment of non-small cell bronchogenic carcinoma. Cancer Treat Rep. 65:1981;947-954.
17. Gralla R.J., Cvitkovic E., Golbey R.B. cis-Dichlorodiammineplatinum(II) in non-small cell carcinoma of the lung. Cancer Treat Rep. 63:1979;1585-1588.
18. Rapp E., Pater J.L., Willan A., Cormier Y., Murray N., Evans W.K.et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer - report of a Canadian multicenter randomized trial. J Clin Oncol. 6:1988;633-641.
19. Williams C.J., Woods R., Levi J., Page J. Chemotherapy for non-small cell lung cancer: a randomized trial of cisplatin/vindesine v no chemotherapy. Semin Oncol. 15:1988;58-61.
20. Ruckdeschel J.C., Finkelstein D.M., Ettinger D.S., Creech R.H., Mason B.A., Joss R.A.et al. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol. 4:1986;14-22.
21. Shepard K.V., Golomb H.M., Bitran J.D., Hoffman P.C., Newman S.B., DeMeester T.R.et al. CAMP chemotherapy for metastatic non-oat cell bronchogenic carcinoma. A 7-year experience (1975-1981) with 160 patients. Cancer. 56:1985;2385-2390.
22. Zwelling L.A., Kohn K.W. Mechanism of action of cis- dichlorodiammineplatinum(II). Cancer Treat Rep. 63:1979;1439-1444.
23. Cosaert J., Quoix E. Platinum drugs in the treatment of non-small-cell lung cancer. Br J Cancer. 87:2002;825-833.
24. McKeage M.J. Comparative adverse effect profiles of platinum drugs. Drug Saf. 13:1995;228-244.
25. Fauser A.A., Fellhauer M., Hoffmann M., Link H., Schlimok G., Gralla R.J. Guidelines for anti-emetic therapy: acute emesis. Eur J Cancer. 35:1999;361-370.
26. Bunn P.A. Jr. Review of therapeutic trials of carboplatin in lung cancer. Semin Oncol. 16:1989;27-33.
27. von Pawel J., von Roemeling R., Gatzemeier U., Boyer M., Elisson L.O., Clark P.et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J Clin Oncol. 18:2000;1351-1359.
28. Bonomi P., Kim K., Fairclough D., Cella D., Kugler J., Rowinsky E.et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 18:2000;623-631.
29. Wozniak A.J., Crowley J.J., Balcerzak S.P., Weiss G.R., Spiridonidis C.H., Baker L.H.et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol. 16:1998;2459-2465.
30. Gatzemeier U., von Pawel J., Gottfried M., ten Velde G.P., Mattson K., DeMarinis F.et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 18:2000;3390-3399.
31. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 311:1995;899-909.
32. Sandler A.B., Nemunaitis J., Denham C., von Pawel J., Cormier Y., Gatzemeier U.et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 18:2000;122-130.
33. Gralla R.J., Casper E.S., Kelsen D.P., Braun D.W. Jr., Dukeman M.E., Martini N.et al. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann Intern Med. 95:1981;414-420.
34. Klastersky J., Sculier J.P., Ravez P., Libert P., Michel J., Vandermoten G.et al. A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma. J Clin Oncol. 4:1986;1780-1786.
35. Gandara D.R., Crowley J., Livingston R.B., Perez E.A., Taylor C.W., Weiss G.et al. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol. 11:1993;873-878.
36. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J.et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 346:2002;92-98.
37. Rodriguez J., Pawel J.V., Pluzanska A., Gorbounova V., Fossella F., Kaukel E.et al. A multicenter, randomized phase III study of docetaxel + cisplatin and docetaxel + carboplatin vs vinorelbine + cisplatin in chemotherapy-naive patients with advanced and metastatic non-small cell lung cancer. Proc Am Soc Clin Oncol. 20:2001;314a.
38. Kreisman H., Ginsberg S., Propert K.J., Richards F., Graziano S., Green M. Carboplatin or iproplatin in advanced non-small cell lung cancer: a Cancer and Leukemia Group B Study. Cancer Treat Rep. 71:1987;1049-1052.
39. Bonomi P.D., Finkelstein D.M., Ruckdeschel J.C., Blum R.H., Green M.D., Mason B.et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol. 7:1989;1602-1613.
40. Jodrell D.I., Egorin M.J., Canetta R.M., Langenberg P., Goldbloom E.P., Burroughs J.N.et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol. 10:1992;520-528.
41. Egorin M.J., Van Echo D.A., Olman E.A., Whitacre M.Y., Forrest A., Aisner J. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum. Cancer Res. 45:1985;6502-6506.
42. Ramalingam S., Bonomi P., Dobbs T., Wojtovicz-Praga S., Cascino M., Belani C. Docetaxel and carboplatin for advanced non-small cell lung cancer (NSCLC): dose of carboplatin influences outcome. Presented at the annual meeting of the American Society of Clinical Oncology. Orlando (FL), May 18-21, 2002.
43. Rosell R., Gatzemeier U., Betticher D.C., Keppler U., Macha H.N., Pirker R.et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol. 13:2002;1539-1549.
44. Klastersky J., Sculier J.P., Lacroix H., Dabouis G., Bureau G., Libert P.et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol. 8:1990;1556-1562.
45. Raymond E., Chaney S.G., Taamma A., Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 9:1998;1053-1071.
46. Monnet I., de C.H., Soulie P., Saltiel-Voisin S., Bekradda M., Saltiel J.C.et al. Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicenter phase II study. Ann Oncol. 13:2002;103-107.
47. Hoffman P.C., Mauer A.M., Otterson G.A., Rudin C.M., Villalona-Calero M.A., Golomb H.M.et al. Phase II study of oxaliplatin (OX) and paclitaxal (PA) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. May 18-21, 2002.
48. Eisenhauer E.A., Vermorken J.B. The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs. 55:1998;5-30.
49. Milas L., Milas M.M., Mason K.A. Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol. 9:1999;12-26.
50. Vacca A., Ribatti D., Iurlaro M., Merchionne F., Nico B., Ria R.et al. Docetaxel versus paclitaxel for antiangiogenesis. J Hematother Stem Cell Res. 11:2002;103-118.
51. Verweij J., Clavel M., Chevalier B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol. 5:1994;495-505.
52. Chang A.Y., Kim K., Glick J., Anderson T., Karp D., Johnson D. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst. 85:1993;388-394.
53. Alberola V., Rosell R., Gonzalez-Larriba J.L., Molina F., Ayala F., Garcia-Conde J.et al. Single agent Taxol, 3-hour infusion, in untreated advanced non-small-cell lung cancer. Ann Oncol. 6(Suppl 3):1995;S49-S52.
54. Gatzemeier U., Heckmayr M., Neuhauss R., Schluter I., Pawel J.V., Wagner H.et al. Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer. Lung Cancer. 12(Suppl 2):1995;S101-S106.
55. Lilenbaum R.C., Herndon J.E. II, List M., Desch C., Watson D., Holland J.et al. Single agent versus combination chemotherapy in patients with advanced non-small cell lung cancer: a CALGB randomized trial of efficacy, quality of life and cost-effectiveness. Proc Am Soc Clin Oncol. 21:2002;1.
56. Kelly K., Pan Z., Murphy J., Huffman D.H., Bunn P.A. Jr. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer. Clin Cancer Res. 3:1997;1117-1123.
57. 2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol. 11:2000;799-805.
58. Akerley W., Choy H., Safran H., Sikov W., Rege V., Sambandam S.et al. Weekly paclitaxel in patients with advanced lung cancer: preliminary data from a phase II trial. Semin Oncol. 24:1997;S12-S13.
59. Akerley W., Glantz M., Choy H., Rege V., Sambandam S., Joseph P.et al. Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol. 16:1998;153-158.
60. Belani C.P., Barstis J., Perry M., Larocca R., Nattam S., Clark R.et al. Phase II multicenter randomized trial of weekly paclitaxel (P) administered in combination with carboplatin followed by maintenance P vs observation for patients with advanced and metastatic non-small cell lung cancer. Proc Am Soc Clin Oncol. 20:2001;323a.
61. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer. 75:1995;968-972.
62. Cerny T., Kaplan S., Pavlidis N., Schoffski P., Epelbaum R., van Meerbeek J.et al. Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br J Cancer. 70:1994;384-387.
63. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M. et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 18:2000;2095-2103.
64. Ramalingam S., Belani C.P. Taxanes for advanced non-small cell lung cancer. Expert Opin Pharmacother. 3:2002;1693-1709.
65. Edelman M.J., Gandara D.R. Promising new agents in the treatment of non-small cell lung cancer. Cancer Chemother Pharmacol. 37:1996;385-393.
66. Sandler A., Ettinger D.S. Gemcitabine: single-agent and combination therapy in non-small cell lung cancer. Oncologist. 4:1999;241-251.
67. Anderson H., Hopwood P., Stephens R.J., Thatcher N., Cottier B., Nicholson M.et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group: Non-Small Cell Lung Cancer. Br J Cancer. 83:2000;447-453.
68. Sederholm C. Gemcitabine compared with gemcitabine plus carboplatin in advanced non-small cell lung cancer: A phase III study by the Swedish Lung Cancer Study Group. Proc Am Soc Clin Oncol. 21:2002;291a.
69. Grunewald R., Kantarjian H., Keating M.J., Abbruzzese J., Tarassoff P., Plunkett W. Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia. Cancer Res. 50:1990;6823-6826.
70. Ceribelli A., Gridelli C., DeMarinis F., Fabi A., Gamucci T., Cortesi E.et al. Prolonged gemcitabine infusion in NSCLC: randomized phase II study of two different schedules in combination with cisplatin. Proc Am Soc Clin Oncol. 21:2002;328a.
71. Gridelli C., Perrone F., Gallo C., Cigolari S., Rossi A., Piantedosi F. et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst. 95:2003;362-372.
72. van Putten J.W., Baas P., Codrington H., Kwa H.B., Muller M., Aaronson N.et al. Activity of single-agent gemcitabine as second-line treatment after previous chemotherapy or radiotherapy in advanced non-small-cell lung cancer. Lung Cancer. 33:2001;289-298.
73. Sculier J.P., Lafitte J.J., Berghmans T., Thiriaux J., Lecomte J., Efremidis A.et al. A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer. The European Lung Cancer Working Party.101473.1044@compuserve.com. Lung Cancer. 29:2000;67-73.
74. Gridelli C., Perrone F., Gallo C., Rossi A., Barletta E., Barzelloni M.L.et al. Single-agent gemcitabine as second-line treatment in patients with advanced non small cell lung cancer (NSCLC): a phase II trial. Anticancer Res. 19:1999;4535-4538.
75. Milas L., Fujii T., Hunter N., Elshaikh M., Mason K., Plunkett W.et al. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res. 59:1999;107-114.
76. Crawford J., O'Rourke M., Schiller J.H., Spiridonidis C.H., Yanovich S., Ozer H.et al. Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. J Clin Oncol. 14:1996;2774-2784.
77. Depierre A., Lemarie E., Dabouis G., Garnier G., Jacoulet P., Dalphin J.C. A phase II study of Navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol. 14:1991;115-119.
78. Le Chevalier T., Brisgand D., Douillard J.Y., Pujol J.L., Alberola V., Monnier A.et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol. 12:1994;360-367.
79. Depierre A., Chastang C., Quoix E., Lebeau B., Blanchon F., Paillot N.et al. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol. 5:1994;37-42.
80. Kelly K., Crowley J., Bunn P.A. Jr., Presant C.A., Grevstad P.K., Moinpour C.M.et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 19:2001;3210-3218.
81. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 91:1999;66-72.
82. Langer C.J. The emerging world role of irinotecan in lung cancer. Oncology (Huntingt). 15:2001;15-21.
83. Fukuoka M., Niitani H., Suzuki A., Motomiya M., Hasegawa K., Nishiwaki Y.et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol. 10:1992;16-20.
84. Negoro S., Masuda N., Takada Y., Sugiura T., Kudoh S., Katakami N.et al. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer. 88:2003;335-341.
85. Takeda K., Negoro S., Kudoh S., Okishio K., Masuda N., Takada M.et al. Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer. Br J Cancer. 79:1999;1462-1467.
86. Furuse K., Fukuoka M., Kawahara M., Nishikawa H., Takada Y., Kudoh S.et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 17:1999;2692-2699.
87. Curran W., Scott C., Langer C.J., Komaki R., Lee J.S., Hauser S.et al. Phase III comparison of sequential vs concurrent chemoradiation for patients (Pts) with unresected stage III non-small cell lung cancer (NSCLC): initial report of radiation therapy oncology group (RTOG) 9410. Proc Am Soc Clin Oncol. 19:2000;484a.
88. Fukuoka M., Yano S., Vansteenkiste G., Kudo S., Averbuch S., Macleod A. et al. Final results from a phase II trial of ZD 1839 for patients with advanced non-small cell lung cancer (IDEAL1). Proc Am Soc Clin Oncol. 21:2002;298a.
89. Kris M.G., Natale N.B., Herbst R.S., Lynch T.J., Prager D., Belani C.P. et al. A phase II trial of ZD 1839 in advanced non-small cell lung cancer patients who had failed platinum- and docetaxel-based regimens (IDEAL2). Proc Am Soc Clin Oncol. 21:2002;292.
90. Kalemkerian G.P. Biology of lung cancer. Curr Opin Oncol. 6:1994;147-155.
91. Fujino M., Dosaka-Akita H., Harada M., Hiroumi H., Kinoshita I., Akie K.et al. Prognostic significance of p53 and ras p21 expression in nonsmall cell lung cancer. Cancer. 76:1995;2457-2463.
92. Salgia R., Skarin A.T. Molecular abnormalities in lung cancer. J Clin Oncol. 16:1998;1207-1217.
93. Mountain C.F. Revisions in the international system for staging lung cancer. Chest. 111:1997;1710-1717.
94. Ohgami A., Mitsudomi T., Sugio K., Tsuda T., Oyama T., Nishida K.et al. Micrometastatic tumor cells in the bone marrow of patients with non-small cell lung cancer. Ann Thorac Surg. 64:1997;363-367.
95. Cote R.J., Beattie E.J., Chaiwun B., Shi S.R., Harvey J., Chen S.C.et al. Detection of occult bone marrow micrometastases in patients with operable lung carcinoma. Ann Surg. 222:1995;415-423. [discussion: 423-5].
96. Rosell R., Sanchez J.M., Taron M., O'Brate A., Gutierrez J.L., Monzo M. et al. Novel approaches in the treatment of non-small-cell lung cancer. Oncology (Huntingt). 15:2001;52-60.
97. Lord R.V., Brabender J., Gandara D., Alberola V., Camps C., Domine M.et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 8:2002;2286-2291.
98. Monzo M., Rosell R., Sanchez J.J., Lee J.S., O'Brate A., Gonzalez-Larriba J.L.et al. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol. 17:1999;1786-1793.
99. Perez-Soler R., Chachoua A., Huberman M., Karp D., Rigas J., Hammond L. et al. A Phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 20:2001;310a.
100. Mitsudomi T., Oyama T., Kusano T., Osaki T., Nakanishi R., Shirakusa T. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J Natl Cancer Inst. 85:1993;2018-2023.
101. Carbone D.P., Mitsudomi T., Chiba I., Piantadosi S., Rusch V., Nowak J.A.et al. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. Chest. 106:1994;377S-381S.
102. Mitsudomi T., Viallet J., Mulshine J.L., Linnoila R.I., Minna J.D., Gazdar A.F. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene. 6:1991;1353-1362.
103. Ohsaki Y., Toyoshima E., Fujiuchi S., Matsui H., Hirata S., Miyokawa N. et al. bcl-2 and p53 protein expression in non-small cell lung cancers: correlation with survival time. Clin Cancer Res. 2:1996;915-920.
104. Hida T., Yatabe Y., Achiwa H., Muramatsu H., Kozaki K., Nakamura S.et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. 58:1998;3761-3764.
105. Dy G.K., Adjei A.A. Novel targets for lung cancer therapy: part I. J Clin Oncol. 20:2002;2881-2894.
106. Kratzke R.A., Greatens T.M., Rubins J.B., Maddaus M.A., Niewoehner D.E., Niehans G.A.et al. Rb and p16INK4a expression in resected non-small cell lung tumors. Cancer Res. 56:1996;3415-3420.